| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H31ClO2 |
| Molecular Weight | 362.933 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@H](C)[C@H](C(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])C[C@H](Cl)C4=CC(=O)CC[C@]34C
InChI
InChIKey=UMRURYMAPMZKQO-NDKKBYRMSA-N
InChI=1S/C22H31ClO2/c1-12-9-17-15-11-19(23)18-10-14(25)5-7-21(18,3)16(15)6-8-22(17,4)20(12)13(2)24/h10,12,15-17,19-20H,5-9,11H2,1-4H3/t12-,15-,16+,17+,19+,20-,21-,22+/m1/s1
| Molecular Formula | C22H31ClO2 |
| Molecular Weight | 362.933 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Clometherone is an investigational derivative of progesterone, possessing antiestrogen and antiandrogen activities. It was developed by Eli Lilly in the 1960s and was found to significantly suppress the estrone induced uterine hypertrophy in mice at an oral or subcutaneous dose of 10ug. In a clinical trial, administration of clometherone to adult males lead to a slight increase in sebum production.
